Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 10/20 | 0.56 |
| ▸ | TLR2 | O60603 | 10/20 | 0.56 |
| ▸ | MAOA | P21397 | 7/20 | 0.48 |
| ▸ | MAOB | P27338 | 7/20 | 0.48 |
| ▸ | FBP1 | P09467 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230981 | 1.00 | TLR4 (0.56) | TLR4TLR2MAOAMAOBFBP1 | |
| SCHEMBL23684551 | 0.82 | FBP1 (0.60) | TLR4TLR2MAOAMAOBFBP1 | |
| SCHEMBL3235702 | 0.79 | MAOA (0.70) | TLR4TLR2MAOAMAOBFBP1 | |
| SCHEMBL3235707 | 0.79 | MAOA (0.70) | TLR4TLR2MAOAMAOBFBP1 | |
| SCHEMBL7418058 | 0.79 | TLR4 (0.56) | TLR4TLR2MAOAMAOBFBP1 | |
| SCHEMBL3230270 | 0.79 | KAT6A (0.40) | MAOAMAOBMAPT | |
| SCHEMBL2285892 | 0.78 | FBP1 (0.67) | FBP1MAPT | |
| SCHEMBL2285894 | 0.78 | FBP1 (0.67) | FBP1MAPT | |
| SCHEMBL7999136 | 0.77 | TLR4 (0.67) | TLR4TLR2MAOAMAOBFBP1 | |
| SCHEMBL6793710 | 0.74 | KAT6A (0.43) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745438-B2 | 3-(2-acylamino-1-hydroxyethyl)-morpholine derivatives and their use as bace inhibitors | ELI LILLY AND COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2091928-A2 | 3-(2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| WO-2006034093-A2 | 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELLI LILLY AND COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | TLR4 4875/4885TLR2 4732/4885MAOA 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.